Novel anti-bmpr1b antibodies and methods of use

Abstract

Provided are novel anti-BMPR1B antibodies and antibody drug conjugates, and methods of using such anti-BMPR1B antibodies and antibody drug conjugates to treat cancer.

1 - 58 . (canceled) 
     
     
         59 . An isolated antibody that binds to BMPR1B and comprises three complementarity determining regions of a light chain variable region set forth as SEQ ID NO: 21 and three complementarity determining regions of a heavy chain variable region set forth as SEQ ID NO: 23. 
     
     
         60 . The isolated antibody of  claim 59 , wherein the antibody comprises residues 24-34 of SEQ ID NO: 21 for CDR-L1, residues 50-56 of SEQ ID NO: 21 for CDR-L2, residues 89-97 of SEQ ID NO: 21 for CDR-L3, residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2, and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to Kabat. 
     
     
         61 . The isolated antibody of  claim 59 , wherein the antibody comprises residues 24-34 of SEQ ID NO: 21 for CDR-L1, residues 50-56 of SEQ ID NO: 21 for CDR-L2, residues 89-97 of SEQ ID NO: 21 for CDR-L3, residues 26-32 of SEQ ID NO: 23 for CDR-H1, residues 52-56 of SEQ ID NO: 23 for CDR-H2, and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to Chothia. 
     
     
         62 . The isolated antibody of  claim 59 , wherein the antibody comprises residues 30-36 of SEQ ID NO: 21 for CDR-L1, residues 46-55 of SEQ ID NO: 21 for CDR-L2, residues 89-96 of SEQ ID NO: 21 for CDR-L3, residues 30-35 of SEQ ID NO: 23 for CDR-H1, residues 47-58 of SEQ ID NO: 23 for CDR-H2, and residues 93-101 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to MacCallum. 
     
     
         63 . The isolated antibody of  claim 59 , wherein the antibody comprises residues 24-34 of SEQ ID NO: 21 for CDR-L1, residues 50-56 of SEQ ID NO: 21 for CDR-L2, residues 89-97 of SEQ ID NO: 21 for CDR-L3, residues 26-35 of SEQ ID NO: 23 for CDR-H1, residues 50-58 of SEQ ID NO: 23 for CDR-H2, and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to AbM. 
     
     
         64 . The isolated antibody of  claim 59 , wherein the antibody comprises a light chain variable region set forth as SEQ ID NO: 21 and a heavy chain variable region set forth as SEQ ID NO: 23. 
     
     
         65 . The isolated antibody of  claim 59 , wherein the antibody is a chimeric, CDR grafted, humanized, or human antibody, or an immunoreactive fragment thereof. 
     
     
         66 . The isolated antibody of  claim 59 , wherein the antibody is a monoclonal antibody. 
     
     
         67 . The isolated antibody of  claim 59 , wherein the antibody is a murine antibody. 
     
     
         68 . The isolated antibody of  claim 59 , wherein the antibody is conjugated to a payload. 
     
     
         69 . The isolated antibody of  claim 60 , wherein the antibody is conjugated to a payload. 
     
     
         70 . A nucleic acid encoding all or part of the antibody of  claim 59 . 
     
     
         71 . A vector comprising the nucleic acid of  claim 70 . 
     
     
         72 . A host cell comprising the nucleic acid of  claim 70 . 
     
     
         73 . A pharmaceutical composition comprising the antibody of  claim 59 . 
     
     
         74 . A pharmaceutical composition comprising the antibody of  claim 60 . 
     
     
         75 . A pharmaceutical composition comprising the antibody of  claim 61 . 
     
     
         76 . A pharmaceutical composition comprising the antibody of  claim 64 . 
     
     
         77 . A pharmaceutical composition comprising the antibody of  claim 68 . 
     
     
         78 . A pharmaceutical composition comprising an antibody conjugated to a payload, wherein the antibody comprises a light chain variable region set forth as SEQ ID NO: 21 and a heavy chain variable region set forth as SEQ ID NO: 23.